AbbVie price target raised to $215 from $208 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on AbbVie (ABBV) to $215 from $208 and keeps an Outperform rating on the shares. The company’s Skyrizi and Rinvoq $4B guidance increase firmly outlines growth profile for AbbVie in the second half of the decade, moving on from the Humira loss of exclusivity narrative, the analyst tells investors in a research note.